Lisata Therapeutics Inc. has announced positive preclinical results from studies evaluating its proprietary iRGD cyclic peptide product candidate, certepetide, as part of antibody-drug conjugate $(ADC)$ combinations. The results were presented by Lisata's licensing partner, Catalent, Inc., at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025. Data from Catalent's studies showed that incorporating certepetide as a non-cytotoxic payload in its SMARTag® ADC technology improved tumor-selective penetration and efficacy, and broadened the distribution of the cytotoxic payload within the tumor microenvironment. The findings reinforce evidence that certepetide can enhance the targeting and effectiveness of therapeutic agents in which it is incorporated or co-administered.